Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. PRIM
2. ABBV
3. IBM
4. META
5. NAVN
6. DFTX
7. CNC
8. KFY
9. SPY
10. MU

Go back to Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer
ImaRx Therapeutics, Inc. (NASDAQ: IMRX) Delayed: 4.44 --0 (-0%)
Previous Close $4.44    52 Week High $0.04 
Open $4.44    52 Week Low $0.00 
Day High $4.44    P/E N/A 
Day Low $4.44    EPS $-0.09 
Volume 2,176       

TEVA PHARMACEUTICAL INDUSTRIES (NYSE: TEVA) Delayed: 32.20 --0 (-0%)
Previous Close $32.20    52 Week High $66.55 
Open $32.20    52 Week Low $37.82 
Day High $32.20    P/E N/A 
Day Low $32.20    EPS $0.00 
Volume 12,763       

TEVA PHARMACEUTICAL INDUSTRIES (NYSE: TEVA) Delayed: 32.20 --0 (-0%)
Previous Close $32.20    52 Week High $66.55 
Open $32.20    52 Week Low $37.82 
Day High $32.20    P/E N/A 
Day Low $32.20    EPS $0.00 
Volume 12,763